Cash tills are ringing at GlaxoSmithKline thanks to soaring demand for its swine flu vaccine Pandemrix, and Relenza, which treats the symptoms of the illness that has led to hundreds of deaths around the world. Analysts predict a 1bn revenue windfall in 2010 as governments stockpile medicines designed to combat a possible pandemic.
http://www.guardian.co.uk/business/2010/jan/10/glaxosmithkline-swine-flu-revenue-boost
Add to My Watchlist
What is My Watchlist?